{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:42Z","timestamp":1792277922037,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["1RO1-MH-116695"],"award-info":[{"award-number":["1RO1-MH-116695"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI-050409"],"award-info":[{"award-number":["P30-AI-050409"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since HIV-associated neurocognitive disorders (HANDs) occur in up to half of HIV-positive individuals, even with combined antiretroviral therapy (cART), adjunctive therapies are needed. Chronic CNS inflammation contributes to HAND and HIV encephalitis (HIVE). Baricitinib is a JAK 1\/2 inhibitor approved in the USA, EU, and Japan for rheumatoid arthritis, demonstrating potent inhibition of IL-6, D-dimer, CRP, TNF-\u03b1, IFN-\u03b1\/\u03b2, and other pro-inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our modified murine HAND model was used to evaluate the ability of baricitinib to cross the blood-brain barrier (BBB) and modulate monocyte\/macrophage-driven HAND. Severity of HAND was measured by assessing cognitive performance of low- and high-dose baricitinib treated versus untreated HAND mice. The severity of brain neuroinflammation was evaluated in these mouse groups after flow cytometric analyses. We also assessed the ability of baricitinib to block events in myeloid and lymphoid cells in vitro that may undergird the persistence of HIV in the central nervous system (CNS) in primary human macrophages (M\u03d5) and lymphocytes including HIV replication, HIV-induced activation, reservoir expansion, and reservoir maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In vivo, both doses of 10 and 50\u2009mg\/kg qd baricitinib crossed the BBB and reversed behavioral abnormalities conferred by HIV infection. Moreover, baricitinib significantly reduced HIV-induced neuroinflammation marked by glial activation: activated microglia (MHCII\n                      <jats:sup>+<\/jats:sup>\n                      \/CD45\n                      <jats:sup>+<\/jats:sup>\n                      ) and astrogliosis (GFAP). Baricitinib also significantly reduced the percentage of p24+ human macrophages in mouse brains (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 versus HAND mice;\n                      <jats:italic>t<\/jats:italic>\n                      test). In vitro, baricitinib significantly reduced markers of persistence, reservoir size, and reseeding in M\u03d5.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results show that blocking the JAK\/STAT pathway reverses cognitive deficits and curtails inflammatory markers in HAND in mice. Our group recently reported safety and tolerability of ruxolitinib in HIV-infected individuals (Marconi et al., Safety, tolerability and immunologic activity of ruxolitinib added to suppressive ART, 2019), underscoring potential safety and utility of JAK inhibitors for additional human trials. The data reported herein coupled with our recent human trial with JAK inhibitors provide compelling preclinical data and impetus for considering a trial of baricitinib in HAND individuals treated with cART to reverse cognitive deficits and key events driving viral persistence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-019-1565-6","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T01:53:09Z","timestamp":1569549189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro"],"prefix":"10.1186","volume":"16","author":[{"given":"Christina","family":"Gavegnano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldeab B.","family":"Haile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-4842","authenticated-orcid":false,"given":"William R.","family":"Tyor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"1565_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/infdis\/jiw505","volume":"215","author":"AM Anderson","year":"2017","unstructured":"Anderson AM, Munoz-Moreno JA, DR MC, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, JC MA, JA MC, Morgello S, Sacktor N, Simpson DM, Franklin DR, Heaton RK, Grant I, Letendre SL, Group C. Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. J Infect Dis. 2017;215:105\u201313.","journal-title":"J Infect Dis"},{"key":"1565_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QCO.0000000000000328","volume":"30","author":"DB Clifford","year":"2017","unstructured":"Clifford DB. HIV-associated neurocognitive disorder. Curr Opin Infect Dis. 2017;30:117\u201322.","journal-title":"Curr Opin Infect Dis"},{"key":"1565_CR3","first-page":"70","volume":"8","author":"TZ Griffin","year":"2015","unstructured":"Griffin TZ, Kang W, Ma Y, Zhang M. The HAND database: a gateway to understanding the role of HIV in HIV-associated neurocognitive disorders. BMC Med Genet. 2015;8:70.","journal-title":"BMC Med Genet"},{"key":"1565_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajmg.b.32530","volume":"174","author":"P Jia","year":"2017","unstructured":"Jia P, Zhao Z, Hulgan T, Bush WS, Samuels DC, Bloss CS, Heaton RK, Ellis RJ, Schork N, Marra CM, Collier AC, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, JA MC, Barnholtz-Sloan JS, Franklin DR, Rosario D, Letendre SL, Grant I, Kallianpur AR, Group CS. Genome-wide association study of HIV-associated neurocognitive disorder (HAND): a CHARTER group study. Am J Med Genet B Neuropsychiatr Genet. 2017;174:413\u201326.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1565_CR5","doi-asserted-by":"publisher","first-page":"E1738","DOI":"10.1073\/pnas.1525528113","volume":"113","author":"ML Bennett","year":"2016","unstructured":"Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, Weissman IL, Chang EF, Li G, Grant GA, Hayden Gephart MG, Barres BA. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A. 2016;113:E1738\u201346.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1565_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.expneurol.2007.03.007","volume":"205","author":"J Cook-Easterwood","year":"2007","unstructured":"Cook-Easterwood J, Middaugh LD, Griffin WC 3rd, Khan I, Tyor WR. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol. 2007;205:506\u201312.","journal-title":"Exp Neurol"},{"key":"1565_CR7","first-page":"109","volume":"10","author":"WC Griffin 3rd","year":"2004","unstructured":"Griffin WC 3rd, Middaugh LD, Cook JE, Tyor WR. The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive function. J Neuro-Oncol. 2004;10:109\u201315.","journal-title":"J Neuro-Oncol"},{"key":"1565_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2016.02.007","volume":"92","author":"WB Haile","year":"2016","unstructured":"Haile WB, Gavegnano C, Tao S, Jiang Y, Schinazi RF, Tyor WR. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis. 2016;92:137\u201343.","journal-title":"Neurobiol Dis"},{"key":"1565_CR9","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1097\/QAD.0b013e3282f08c2f","volume":"21","author":"AR Sas","year":"2007","unstructured":"Sas AR, Bimonte-Nelson HA, Tyor WR. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of interferon-alpha in the brain. AIDS. 2007;21:2151\u20139.","journal-title":"AIDS"},{"key":"1565_CR10","first-page":"180","volume":"24","author":"WR Tyor","year":"2018","unstructured":"Tyor WR, Bimonte-Nelson H. A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments. J Neuro-Oncol. 2018;24:180\u20134.","journal-title":"J Neuro-Oncol"},{"key":"1565_CR11","doi-asserted-by":"publisher","first-page":"e1000842","DOI":"10.1371\/journal.ppat.1000842","volume":"6","author":"TH Burdo","year":"2010","unstructured":"Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, Alvarez X, Kuroda MJ, Williams KC. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog. 2010;6:e1000842.","journal-title":"PLoS Pathog"},{"issue":"2","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ana.25160","volume":"83","author":"Stephen D. Ginsberg","year":"2018","unstructured":"Ginsberg SD, Alldred MJ, Gunnam SM, Schiroli C, Lee SH, Morgello S, Fischer T. Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis. Ann Neurol. 2018. https:\/\/doi.org\/10.1002\/ana.25160 .","journal-title":"Annals of Neurology"},{"key":"1565_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jneumeth.2010.11.001","volume":"194","author":"R Gordon","year":"2011","unstructured":"Gordon R, Hogan CE, Neal ML, Anantharam V, Kanthasamy AG, Kanthasamy A. A simple magnetic separation method for high-yield isolation of pure primary microglia. J Neurosci Methods. 2011;194:287\u201396.","journal-title":"J Neurosci Methods"},{"key":"1565_CR14","unstructured":"Marconi V, Moser C, Gavegnano C, Tsibris A, Kantor A, Overton ET, Flexner CW, Hunt PW, Sekaly RP, DelRio C, Lederman MM, Tressler R, Deeks SG, Lennox JJ, Schinazi RF. Safety, tolerability and immunologic activity of ruxolitinib added to suppressive ART. Oral abstract # 3957. Boston: Conference on Retroviruses and Opportunistic Infections; 2019."},{"key":"1565_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/QAD.0000000000001836","volume":"32","author":"R Koneru","year":"2018","unstructured":"Koneru R, Bimonte-Nelson H, Ciavatta V, Haile W, Elmore K, Ward J, Maroun L, Tyor WR. Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model. AIDS. 2018;32:1403\u201311.","journal-title":"AIDS"},{"key":"1565_CR16","first-page":"9","volume":"20","author":"R Koneru","year":"2014","unstructured":"Koneru R, Olive MF, Tyor WR. Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. J Neuro-Oncol. 2014;20:9\u201317.","journal-title":"J Neuro-Oncol"},{"key":"1565_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/cbin.10516","volume":"39","author":"S Jose","year":"2015","unstructured":"Jose S, Tan SW, Tong CK, Vidyadaran S. Isolation and characterization of primary microglia from post-natal murine brain tissues: a comparison of two methods. Cell Biol Int. 2015;39:1355\u201363.","journal-title":"Cell Biol Int"},{"key":"1565_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuroscience.2014.08.023","volume":"279","author":"J Lehmann","year":"2014","unstructured":"Lehmann J, Hartig W, Seidel A, Fuldner C, Hobohm C, Grosche J, Krueger M, Michalski D. Inflammatory cell recruitment after experimental thromboembolic stroke in rats. Neuroscience. 2014;279:139\u201354.","journal-title":"Neuroscience"},{"key":"1565_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneumeth.2008.08.016","volume":"175","author":"R Marek","year":"2008","unstructured":"Marek R, Caruso M, Rostami A, Grinspan JB, Das Sarma J. Magnetic cell sorting: a fast and effective method of concurrent isolation of high purity viable astrocytes and microglia from neonatal mouse brain tissue. J Neurosci Methods. 2008;175:108\u201318.","journal-title":"J Neurosci Methods"},{"key":"1565_CR20","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3389\/fimmu.2017.01666","volume":"8","author":"JM Peralta Ramos","year":"2017","unstructured":"Peralta Ramos JM, Bussi C, Gaviglio EA, Arroyo DS, Baez NS, Rodriguez-Galan MC, Iribarren P. Type I IFNs are required to promote central nervous system immune surveillance through the recruitment of inflammatory monocytes upon systemic inflammation. Front Immunol. 2017;8:1666.","journal-title":"Front Immunol"},{"key":"1565_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1128\/AAC.02012-12","volume":"57","author":"C Gavegnano","year":"2013","unstructured":"Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob Agents Chemother. 2013;57:1262\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1565_CR22","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1128\/AAC.02496-13","volume":"58","author":"C Gavegnano","year":"2014","unstructured":"Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58:1977\u201386.","journal-title":"Antimicrob Agents Chemother"},{"key":"1565_CR23","doi-asserted-by":"publisher","first-page":"e1006740","DOI":"10.1371\/journal.ppat.1006740","volume":"13","author":"C Gavegnano","year":"2017","unstructured":"Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sekaly RP. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathog. 2017;13:e1006740.","journal-title":"PLoS Pathog"},{"key":"1565_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1750-3639.2006.00027.x","volume":"16","author":"MA Cosenza-Nashat","year":"2006","unstructured":"Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS, Lee SC. CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol. 2006;16:256\u201365.","journal-title":"Brain Pathol"},{"key":"1565_CR25","doi-asserted-by":"publisher","first-page":"E5665","DOI":"10.1073\/pnas.1604263113","volume":"113","author":"NH Varvel","year":"2016","unstructured":"Varvel NH, Neher JJ, Bosch A, Wang W, Ransohoff RM, Miller RJ, Dingledine R. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. Proc Natl Acad Sci U S A. 2016;113:E5665\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1565_CR26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","volume":"104","author":"H Kim","year":"2018","unstructured":"Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104:364\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"1565_CR27","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54:1354\u201361.","journal-title":"J Clin Pharmacol"},{"key":"1565_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11904-012-0118-8","volume":"9","author":"PW Hunt","year":"2012","unstructured":"Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV\/AIDS Rep. 2012;9:139\u201347.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"Suppl 2","key":"1565_CR29","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","volume":"214","author":"PW Hunt","year":"2016","unstructured":"Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44\u201350.","journal-title":"J Infect Dis"},{"key":"1565_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1742-2094-10-86","volume":"10","author":"ML Selenica","year":"2013","unstructured":"Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation. 2013;10:86.","journal-title":"J Neuroinflammation"},{"key":"1565_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1326-6-3","volume":"6","author":"J Salemi","year":"2011","unstructured":"Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J, Fernandez F, Tan J, Giunta B. Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener. 2011;6:3.","journal-title":"Mol Neurodegener"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1750-1326-9-58","volume":"9","author":"MD Boska","year":"2014","unstructured":"Boska MD, Dash PK, Knibbe J, Epstein AA, Akhter SP, Fields N, High R, Makarov E, Bonasera S, Gelbard HA, Poluektova LY, Gendelman HE, Gorantla S. Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol Neurodegener. 2014;9:58.","journal-title":"Mol Neurodegener"},{"key":"1565_CR33","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cne.23233","volume":"521","author":"LB Buckman","year":"2013","unstructured":"Buckman LB, Thompson MM, Moreno HN, Ellacott KL. Regional astrogliosis in the mouse hypothalamus in response to obesity. J Comp Neurol. 2013;521:1322\u201333.","journal-title":"J Comp Neurol"},{"key":"1565_CR34","first-page":"431","volume":"22","author":"AJ Levine","year":"2016","unstructured":"Levine AJ, Soontornniyomkij V, Achim CL, Masliah E, Gelman BB, Sinsheimer JS, Singer EJ, Moore DJ. Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. J Neuro-Oncol. 2016;22:431\u201341.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"1565_CR35","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/glia.23292","volume":"66","author":"Ismini E. Papageorgiou","year":"2018","unstructured":"Papageorgiou IE, Valous NA, Lahrmann B, Janova H, Klaft ZJ, Koch A, Schneider UC, Vajkoczy P, Heppner FL, Grabe N, Halama N, Heinemann U, Kann O. Astrocytic glutamine synthetase is expressed in the neuronal somatic layers and down-regulated proportionally to neuronal loss in the human epileptic hippocampus. Glia. 2018. https:\/\/doi.org\/10.1002\/glia.23292 .","journal-title":"Glia"},{"key":"1565_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-1-61779-452-0_21","volume":"814","author":"P Yu","year":"2012","unstructured":"Yu P, Wang H, Katagiri Y, Geller HM. An in vitro model of reactive astrogliosis and its effect on neuronal growth. Methods Mol Biol. 2012;814:327\u201340.","journal-title":"Methods Mol Biol"},{"key":"1565_CR37","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1172\/JCI98968","volume":"128","author":"JB Honeycutt","year":"2018","unstructured":"Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, Swanson MD, Sheridan P, Zakharova O, Prince F, Kuruc J, Gay CL, Evans C, Eron JJ, Wahl A, Garcia JV. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest. 2018;128:2862\u201376.","journal-title":"J Clin Invest"},{"key":"1565_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.4319","volume":"23","author":"JB Honeycutt","year":"2017","unstructured":"Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat Med. 2017;23:638\u201343.","journal-title":"Nat Med"},{"key":"1565_CR39","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.4049\/jimmunol.1003757","volume":"186","author":"L Alammar","year":"2011","unstructured":"Alammar L, Gama L, Clements JE. Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection. J Immunol. 2011;186:4008\u201318.","journal-title":"J Immunol"},{"key":"1565_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/QAD.0000000000002150","volume":"33","author":"BH Kim","year":"2019","unstructured":"Kim BH, Kelschenbach J, Borjabad A, Hadas E, He H, Potash MJ, Nedelcovych MT, Rais R, Haughey NJ, McArthur JC, Slusher BS, Volsky DJ. Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice. AIDS. 2019;33:973\u201384.","journal-title":"AIDS"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T08:58:39Z","timestamp":1611392319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1565-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols were approved by the Atlanta VA Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All co-authors have reviewed the data and manuscript and approved it for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}